The Future of JAK Inhibitors

Will JAK inhibitors triumph over persisting regulatory roadblocks to offer patients a new treatment option?

From blockbuster drugs to black box warnings, Janus kinase inhibitors (JAKs) have seen dramatic highs and lows in their journey to market access across the last few years. This innovative drug class has faced dizzying twists, turns and falls within the landscape of safety acceptability. Yet despite the hurdles JAKs are facing, pharma’s conviction in their potential to generate a paradigm shift in patient care means R&D activity and interest remains undaunted.

Driven by the sheer scale of the Immune-Mediated Inflammatory Diseases (IMIDs) treatment market and clear scenario of unmet patient need, the JAKs pipeline currently comprises no fewer than 45 therapeutic candidates. 1 In different stages of development, they are in a whole slew of IMID fields – and their journey is far from over.

JAK inhibitors are an oral class of therapeutics exciting to biopharma companies, investors, patients and physicians alike. Clinical results promise patients in multiple indications effective and more convenient treatment options. The first assets to enter the market, with approval for Rheumatoid Arthritis (RA), were tofacitinib (now also approved for Psoriatic Arthritis and Ulcerative Colitis) and baricitinib, followed by upadacitinib (RA).

First-generation JAKs have proven spectacularly efficacious both in clinical trials and in the clinic in treating inflammatory and autoimmune diseases – however, nearly all are facing an imbalance between safety and efficacy.

The result? JAKs’ rise in market success – for now – has hit unexpected turbulence.

Deallus JAK Inhibitors White Paper
DOWNLOAD WHITEPAPER

You may also be interested in…

Deallus welcomes George Gu, Principal & Head of China, Shanghai

Deallus is delighted to announce that George Gu joined our team on the 6th of April. Medical Doctor by training - focusing on Radiation Oncology - George has spent the last 7 years working with various consulting and start-up companies, gaining valuable experience in medical internet and genomic profiling companies.

Deallus welcomes Kunal Kaushal Principal, New York

Deallus welcomes Kunal Kaushal as a Principal in the New York office. Kunal brings more than 14 years of strategy consulting and advisory experience to the role, his expertise spanning many different project types, geographies, and therapeutic areas. His TA focus includes Oncology, Cardiovascular, Gastrointestinal, Anti-Obesity and Rheumatology.

CARe To Understand What Will Shape CAR T’s Future?

CAR T-cell therapies space is complex, highly competitive, and quickly evolving. Add the pandemic to the mix and the logistical, reimbursement, and pricing landscape grows even more complicated. In this in-depth paper we research the current state of CAR T-cell therapies and speculate on the factors currently making the largest impact - China, Commercialization, and COVID-19. Read more for a comprehensive, well-researched take on the space.

  • COVID-19-Ondemand-Webinar Leading in a Crisis

OnDemand Webinar – Leading in a crisis

Peter Hempshall, Deallus CEO, and Rita Numerof, President & Co-Founder of Numerof & Associates, have joined forces to generate thought-provoking discussion series on Navigating Market Disruption. Episode two is Leading in a crisis. Rita and Pete will discuss why focus and remaining agile during and after a crisis are essential for success. Executives looking for practical advice on how to balance agility and governance processes will find this discussion valuable.